Clinical Trial Update: A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of BKM120 (a PI3K inhibitor) in triple-negative metastatic breast cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-10-28